# Ki Hyeong Lee

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ki-hyeong-lee/

## Facts

| Field | Value |
| --- | --- |
| Citations | 52,687 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 78 |
| i10-index | 234 |
| Last Known Institution | Chungbuk National University Hospital |
| OpenAlex ID | https://openalex.org/A5005962138 |
| ORCID iD | https://orcid.org/0000-0002-7830-5950 |
| Works | 512 |

## Researcher papers

Showing 12 of 32.

- [Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-untreated-i-egfr-i-mutated-advanced-non-small-cell-lung-cancer/)
- [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/)
- [Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer/)
- [Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations](https://scholariq.org/papers/phase-iii-study-of-afatinib-or-cisplatin-plus-pemetrexed-in-patients-with/)
- [Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-untreated-i-egfr-i-mutated-advanced-nsclc/)
- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials](https://scholariq.org/papers/afatinib-versus-cisplatin-based-chemotherapy-for-egfr-mutation-positive-lung/)
- [Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/dacomitinib-versus-gefitinib-as-first-line-treatment-for-patients-with-egfr/)
- [Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-i-alk-i-positive-non-small-cell-lung-cancer/)
- [First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung](https://scholariq.org/papers/first-signal-first-line-single-agent-iressa-versus-gemcitabine-and-cisplatin/)
- [Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study](https://scholariq.org/papers/amivantamab-in-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/)
- [Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-resected-i-egfr-i-mutated-nsclc/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [Chungbuk National University Hospital](https://scholariq.org/institutions/chungbuk-national-university-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.